UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

UCB SA (UCB) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH33857FSA
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

UCB SA (UCB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Jun 28,2018: New UCB Research Showcases Value of CIMZIA (certolizumab pegol) in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient Populations

Jun 19,2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma-UCB SA]

Jun 15,2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey

Jun 01,2018: UCB proud to collect Wallonia Export Award

May 22,2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

UCB SA-Key Facts 6

UCB SA-Key Employees 7

UCB SA-Key Employee Biographies 8

UCB SA-Major Products and Services 9

UCB SA-History 10

UCB SA-Company Statement 17

UCB SA-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Joint Venture 22

Section 2-Company Analysis 23

Company Overview 23

UCB SA-Business Description 24

UCB SA-Corporate Strategy 25

UCB SA-SWOT Analysis 26

SWOT Analysis-Overview 26

UCB SA-Strengths 26

UCB SA-Weaknesses 27

UCB SA-Opportunities 28

UCB SA-Threats 29

UCB SA-Key Competitors 30

Section 3-Company Financial Ratios 31

Financial Ratios-Capital Market Ratios 31

Financial Ratios-Annual Ratios 32

Performance Chart 35

Financial Performance 35

Financial Ratios-Interim Ratios 36

Financial Ratios-Ratio Charts 37

Section 4-Company's Lifesciences Financial Deals and Alliances 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39

UCB SA, Recent Deals Summary 40

Section 5-Company's Recent Developments 41

Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma-UCB SA] 41

Jun 15, 2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey 42

Jun 01, 2018: UCB proud to collect Wallonia Export Award 43

May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 44

May 07, 2018: Partnership with Science 37: helping UCB to improve patient experience 45

May 03, 2018: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home 46

Apr 23, 2018: Sharing research & supporting development of future neurology leaders at AAN 2018 47

Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 49

Mar 21, 2018: GoBoldy: R&D Is An Investment In New Era Of Medicine 50

Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 51

Section 6-Appendix 52

Methodology 52

Ratio Definitions 52

About GlobalData 56

Contact Us 56

Disclaimer 56

List of Figures

UCB SA, Performance Chart (2013-2017) 35

UCB SA, Ratio Charts 37

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 39

List of Tables

UCB SA, Key Facts 6

UCB SA, Key Employees 7

UCB SA, Key Employee Biographies 8

UCB SA, Major Products and Services 9

UCB SA, History 10

UCB SA, Subsidiaries 19

UCB SA, Joint Venture 22

UCB SA, Key Competitors 30

UCB SA, Ratios based on current share price 31

UCB SA, Annual Ratios 32

UCB SA, Annual Ratios (Cont...1) 33

UCB SA, Annual Ratios (Cont...2) 34

UCB SA, Interim Ratios 36

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39

UCB SA, Recent Deals Summary 40

Currency Codes 52

Capital Market Ratios 52

Equity Ratios 53

Profitability Ratios 53

Cost Ratios 54

Liquidity Ratios 54

Leverage Ratios 55

Efficiency Ratios 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Valeant Pharmaceuticals International Inc

Servier Laboratories Ltd

Novartis AG

Merck Serono SA

Johnson & Johnson

GlaxoSmithKline Plc

Eli Lilly and Co

Biotie Therapies Corp

AstraZeneca Plc

Amgen Inc

UCB SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8613
Site License
USD 250 INR 17225
Corporate User License
USD 375 INR 25838

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com